BioSpace News Archive

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company’s cyclin-dependent kinase (CDK) 2/9 inhibitor, as a novel treatment for metastatic colorectal cancer (CRC).

Regulus Therapeutics Inc. announced that it expects to be added to the broad-market Russell 3000® Index and the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th.

Ascentage Pharma announced that it has released the latest results from a Phase Ib/II study of its Bcl-2 inhibitor lisaftoclax in combination with azacitidine in patients with treatment-naïve or relapsed/refractory acute myeloid leukemia, in a poster presentation at the 60th American Society of Clinical Oncology Annual Meeting taking place in Chicago, IL.

GC Biopharma announced that it will attend 2024 Spring Symposium of the Korean American Society in Biotech and Pharmaceuticals on June 7-8th at Waltham, Massachusetts as a sponsor to share keynote presentation, present Korean Scientist Awards and conduct global recruitment.

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced its participation at key medical and stakeholder meetings in the remainder of 2024.

Innate Pharma SA announced favorable results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides.

ExeVir Bio, a biotech company developing robust heavy chain-only antibody therapies for broad protection against infectious diseases, announced new data demonstrating that its antibodies are exceptionally potent in neutralizing the SARS-CoV-2 variant JN.1, the parental strain of the currently most dominantly circulating variants worldwide.

UNION therapeutics A/S announces successful completion of the ADESOS Phase 2b, randomized, dose-finding study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe AD.

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that the European Medicines Agency has granted Orphan Drug Designation to NT-I7 for the treatment of Acute Radiation Syndrome.

Viseon Inc. announces the completion of an insider financing round. The financing will enable further 4K-ADV™ product development and market expansion focusing on several exciting fronts where digitization of open and minimally invasive surgery can facilitate clinical and economic benefits.